• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » UPDATE: Boston Scientific escapes the junkyard, floats $2 billion bond prospectus

UPDATE: Boston Scientific escapes the junkyard, floats $2 billion bond prospectus

December 10, 2009 By MassDevice staff

Boston Scientific Corp. (NYSE: BSX) wasted no time in looking to capitalize on its escape from the junkyard, at least in the eyes of one rating agency.

Standard & Poor’s Ratings Services raised BSX’s credit rating out of junk bond status, freeing BSX up to raise some cash in an effort to pay down a massive chunk of debt that comes due in April, 2011.

To that end the company put out a bond prospectus, seeking to raise $2 billion through the sale of senior unsecured notes.

The public offering will consist of $850 million in 4.5 percent notes due January 2015, $850 million in 6.00 percent notes due January 2020 and $300 million in 7.375 percent notes due January 2040. It expects the round to close on December 14. BSX will land net proceeds of $1.99 billion, before expenses, according to a regulatory filing.

“We expect to use the net proceeds from this offering for general corporate purposes, including prepaying a portion of our bank term loan due in April 2011,” the company wrote in a prospectus filed with the federal Securities and Exchange Commission.

Another credit agency, Fitch Ratings, tagged the bond offering with a BB+ rating and a “positive” outlook, citing the roughly $744 million in debt Boston Scientific paid off during the last four quarters.

“Fitch expects additional declines to BSX’s leverage in the intermediate term through increased profitability and additional debt reduction,” according to a press release.

But BSX is still looking at a substantial amount of debt, with $100 million worth coming due in 2010, another $3.75 billion due in 2011 and $2.2 billion maturing after 2013. Fitch predicted the company will continue to pay down the 2011 nut and refinance the remainder. Unlike Standard & Poor’s, however, Fitch kept its credit rating for the company as a whole at just under investment grade (meaning at least one company thinks BSX still belongs in the junkyard).*

Back in March, Standard & Poor’s raised BSX to BB+, just below investment grade. The move followed a similar upgrade by Moody’s Investors Service earlier that month; Fitch followed suit in May.

As a result of prep-paying a portion of the loan, BSX said it expects to record a pre-tax charge of approximately $30 million during the fourth quarter.

*Correction, 12/10/2009: Due to a reporting error, this article originally reported that Fitch raised its rating for Boston Scientific out of junk bond status. Return to the corrected sentence.

Filed Under: Business/Financial News, News Well

More recent news

  • Neuronetics names Steven Pfanstiel chief financial officer
  • Medtronic to distribute Future Medical’s peripheral guidewires
  • AtriCure completes enrollment in stroke prevention trial
  • GT Medical raises $53M to support brain tumor treatment
  • Imperative Care, Proximie partner to develop surgical robot to treat stroke

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy